Acute Hemorrhagic Encephalitis Responding to Combined Decompressive Craniectomy, Intravenous Immunoglobulin, and Corticosteroid Therapies: Association with Novel RANBP2 Variant

Abdulla Alawadhi1, Christine Saint-Martin2, Farhan Bhanji3, Myriam Srour1, Jeffrey Atkinson4 and Guillaume Sébire1*

1 Division of Pediatric Neurology, Department of Pediatrics, Montreal Children's Hospital, Montreal, QC, Canada, 2 Department of Medical Imaging, Montreal Children's Hospital, McGill University, Montreal, QC, Canada, 3 Pediatric Intensive Care Unit, Department of Pediatrics, Montreal Children's Hospital, McGill University, Montreal, QC, Canada, 4 Division of Neurosurgery, Department of Surgery, Montreal Children's Hospital, McGill University, Montreal, QC, Canada

Background: Acute hemorrhagic encephalomyelitis (AHEM) is considered as a rare form of acute disseminated encephalomyelitis characterized by fulminant encephalopathy with hemorrhagic necrosis and most often fatal outcome.

Objective: To report the association with Ran Binding Protein (RANBP2) gene variant and the response to decompressive craniectomy and high-dose intravenous methylprednisolone (IVMP) in life-threatening AHEM.

Design: Single case study.

Case report: A 6-year-old girl known to have sickle cell disease (SCD) presented an acquired demyelinating syndrome (ADS) with diplopia due to sudden unilateral fourth nerve palsy. She received five pulses of IVMP (30 mg/kg/day). Two weeks after steroid weaning, she developed right hemiplegia and coma. Brain magnetic resonance imaging showed a left frontal necrotico-hemorrhagic lesion and new multifocal areas of demyelination. She underwent decompressive craniotomy and evacuation of an ongoing left frontoparietal hemorrhage. Comprehensive investigations ruled out vascular and infectious process. The neurological deterioration stopped concomitantly with combined neurosurgical drainage of the hematoma, decompressive craniotomy, IVMP, and intravenous immunoglobulins (IVIG). She developed during the following months Crohn disease and sclerosing cholangitis. After 2-year follow-up, there was no new neurological manifestation. The patient still suffered right hemiplegia and aphasia, but was able to walk. Cognitive/behavioral abilities significantly recovered. A heterozygous novel rare missense variant (c.4993A>G, p.Lys1665Glu) was identified in RANBP2, a gene associated with acute necrotizing encephalopathy. RANBP2 is a protein playing an important role in the energy homeostasis of neuronal cells.
Conclusion: In any ADS occurring in the context of SCD and/or autoimmune condition, we recommend to slowly wean steroids and to closely monitor the patient after weaning to quickly treat any recurrence of neurological symptom with IVMP. This case report, in addition to others, stresses the likely efficacy of combined craniotomy, IVIG, and IVMP treatments in AHEM. RANBP2 mutations may sensitize the brain to inflammation and predispose to AHEM.

Keywords: Crohn disease, sclerosing cholangitis, sickle cell disease, Acute demyelinating encephalomyelitis, RANBP2, encephalitis, Acute necrotizing encephalopathy

INTRODUCTION

Acute hemorrhagic encephalomyelitis (AHEM) or acute hemorrhagic leukoencephalitis is considered a rare and extremely severe form of acute disseminated encephalomyelitis (ADEM). AHEM is characterized by an acute and rapidly progressive encephalopathy including hemorrhagic necrosis of the parenchyma of the central nervous system. It is usually fatal (1–3). Many treatment options have been used including intravenous (IV) steroids, intravenous immunoglobulins (IVIG), and plasmapheresis (4). There have been few reports of survival following early intervention with high-dose corticosteroid therapy and/or decompressive craniotomy (5–9).

RANBP2, a nuclear pore protein, has numerous roles in the cell cycle. RANBP2 is associated with microtubules and mitochondria suggesting roles in intracellular protein trafficking or energy maintenance and homeostasis of neuronal cells. RANBP2 mutations have been reported in acute necrotizing encephalopathy (ANE) which could present with coma, convulsions, and encephalopathy. The hallmark of ANE is multiple, symmetric brain lesions located in the thalami bilaterally, putamina, deep periventricular white matter, cerebellum, and brainstem. It could be triggered by a viral infection in previously healthy children (10).

We report a new case of AHEM associated to a Ran Binding Protein (RANBP)-2 variant and responsive to combined craniotomy, intravenous methylprednisolone (IVMP), and IVIG as inaugural manifestation of multisystemic autoimmunity in a girl with sickle cell disease (SCD).

CASE REPORT

A 6-year-old girl known for SCD treated on folic acid and hydroxyurea was admitted for new-onset diplopia [day 0 (D0): refers to the start of the diplopia] 6 weeks after respiratory tract infection due to rhinovirus. She was diagnosed with a fourth nerve palsy secondary to an acquired demyelinating syndrome. The initial brain magnetic resonance imaging (MRI) performed at D5 after onset of neurological symptom showed left midbrain and pontine edema with expansion of the brainstem, right caudate nucleus, and scattered supratentorial white matter foci of high T2/FLAIR signal (Figure 1). Brain MR angiography (MRA) showed a normal appearing circle of Willis. The cerebrospinal fluid (CSF) obtained by lumber puncture was normal (WBC 1 cells/μl, RBC 0 cells/μl, glucose 2.9 mmol/L, protein 0.18 g/L, and absent oligoclonal bands). The infectious workup including blood bacterial culture, CSF bacterial and viral cultures, and other tests remained negative.

FIGURE 1 | Brain magnetic resonance imaging on first presentation (day 5) showing multiple areas of abnormal signals (white arrowheads): left midbrain high signal on FLAIR sequence (A), left midbrain hypersignal on T2 weighed (T2W) sequence (B), central gadolinium enhancement of left midbrain lesion on T1 sequence (C), and scattered supratentorial white matter foci of high FLAIR signal (D).
nasopharyngeal aspirate (tested for Influenza A, Influenza B, Parainfluenza 1-2-3, Respiratory Syncytial Virus, Adenovirus, Coronavirus 229E, Coronavirus OC43, Metapneumovirus, Enterovirus, and Rhinovirus), and serologies for Epstein-Barr virus, Mycoplasma pneumoniae, HTLV I, HTLV II, HIV1, and Lyme disease were negative. Bartonella Henselae IgG was positive (1:1,280) reflecting a previously acquired common and self-limited infection in our area. Antinuclear antibodies (ANA) were positive (1:160). B12 and folate levels were normal. Smooth muscle antibodies were negative. Anti-mitochondrial antibodies were positive. Sedimentation rate was 65 mm/h. She was treated with five doses of IVMP (30 mg/kg/day) followed by 9 days of oral prednisone (1 mg/kg/day). At discharge, her neurological exam was significant only for vertical diplopia.

She presented 1 month later with 5 days of upper respiratory tract infection symptoms, fever, headache, and a rapidly progressive right-hand weakness (D30) with normal alertness. She had normal blood pressure (120/81 mmHg). She was started on cefotaxime, vancomycin, and acyclovir. White cell count was 13.4 × 10^9/L, hemoglobin was 7.8 g/L, and platelets were 239 × 10^9/L. While in the MRI machine (D30) she deteriorated with vomiting and reduced level of consciousness (Glasgow Coma Scale dropped from 15 to 8 over 30 min). Brain MRI showed a rapid progression over a few sequences of an active bleed involving both superficial and deep gray matter as well as subcortical white matter of the left hemisphere anterior quadrant. Brain MRA was normal (Figures 2A–F). The patient was immediately brought out of the magnet and her physical exam demonstrated unequal dilated pupils. She received IV mannitol and hypertonic saline for the management of acute intracranial hypertension/herniation and was taken for surgery. She underwent left frontotemporoparietal decompressive craniotomy, evacuation of left frontoparietal intracerebral hemorrhage, and insertion of an external ventricular drain (EVD). Upon opening the skull, there was significant dural tension, and on opening the dura mater, there was a large amount of bleeding, in addition to brain swelling and necrosis. Estimated blood loss was 3.5 L. She received 8 units of packed red blood cells, 3 units of cryoprecipitate, 6 units of fresh frozen plasma, and 3 units of platelets. Coagulation profile showed international normalization ratio = 3.38, prothrombin time = 51.2 s, and partial thromboplastin time = 122 s. An intraventricular pressure monitor was inserted. She returned with stable vitals to PICU. At D31, the CT scan showed extensive multi-compartmental bleed involving the left frontoparietal lobes, the interhemispheric fissure, and the left hemispheric arachnoid spaces. New white matter lesions were detected in the left posterior parietal and occipital lobes and in the left caudate head. MRI at D33 showed interval worsening with disseminated gray and white matter non-hemorrhagic lesions in the right cerebral and both cerebellar hemispheres, bilateral deep gray nuclei, as well as new necrotic non-hemorrhagic lesions in the right hemisphere (Figures 2G–I). She was started on IVMP (30 mg/kg/day for 5 days) and IVIG (1 g/kg/day for 2 days). Repeat MRI at D9 showed no new parenchymal hemorrhage and partial resolution of the non-hemorrhagic lesions (Figure 3). Prednisolone was tapered course over 6 weeks. At discharge (D71), she was able to say a few words and had better power of her right side. Brain MRI performed 3 months later showed complete resolution of the non-hemorrhagic non-necrotic lesions, mainly seen in the right cerebral hemisphere and the cerebellum.

Brain biopsy of the hematoma, some small vessels, cortex, and white matter showed necrotic area, reactive and non-specific findings which could be entirely explained by compressive changes adjacent to a hematoma. There was diffuse microglial activation and signs of early microinfarcts. Blood, CSF and urine culture, and PCR (HSV1/2) were negative for bacteria and for viruses. CSF obtained through craniotomy and EVD performed at D32 showed elevated proteins 2.56 g/L, glucose 3.6 mmol/L, white blood cells 9 cells/μL, and red blood cells 1,341 cells/μL. ANA and anti-DNA antibody were negative.

Anti-extractable nuclear antigens (SSA-RO, SSB-LA, smith, RNP) were negative. Serum autoimmune antibodies panel (NMO, NMDAR, AMPA I/II, GAB, MAG, VGCC, MOG, YO, Hu, RI) were negative but GAD antibody was slightly positive, possibly due to the IVIG infusion. EBV showed no signs of recent infection.

After discharge, the patient was started on regular transfusion exchange. Six months later, the patient was diagnosed to have Crohn’s disease and primary sclerosing cholangitis. Two years later, the patient still suffers right hemiparesis but is able to walk without support. She presents an expressive aphasia. Her intellectual abilities are average, or below the mean but in the normal range, except for the speed of information processing, verbal working memory, and some elaborated executive functions.

GENETIC TESTS

A gene panel (Table 1) targeting inflammatory disorders and post-infectious necrotic encephalopathies found a heterozygous RANBP2 missense mutation (NM_006267.4, c.4993A>G, p.Lys1665Glu). This mutation has not been previously reported in the HGMD database. This variant has been observed at a frequency of <0.01% across the entire Broad ExAC dataset of individuals without severe childhood onset disease (6/117,118 alleles). Analysis of amino acid conservation indicates that the wild-type amino acid Lys1665 is conserved in 59 of 60 mammals increasing the likelihood that a change at this position is damaging (SIFT and Align GVGD).

DISCUSSION

Several differential diagnoses of acute encephalopathy in a patient with sickle cell anemia can be considered. An infectious encephalitis, including herpes encephalitis, was ruled out by blood and CSF bacterial and viral cultures and negative HSV I/II PCR. Nasopharyngeal aspirate was negative for viruses. Some infections have been previously associated with necrotizing encephalitis such as Influenza A (11). SCD patients are prone to ischemic or hemorrhagic strokes (12). Primary hemorrhagic stroke is uncommon in pediatric SCD. Most cases were from adults and have been described in the context of previous ischemic stroke, aneurysms, low hemoglobin, acute chest syndrome, and...
FIGURE 2 | Continued
anemia, or acute chest syndrome due to pneumonia (hypoxemia from fat embolism, pulmonary embolism, sudden has been observed in SCD patients in the context of arterial finding of parvovirus B19 infection. Finally, acute encephalitis for our patient, there was no sign of aplasia or any neuroradiological this was attributed to parvovirus B19-induced vasculitis (lar white matter, and mainly along the posterior parietal cortex. punctate areas of hemorrhages in the basal ganglia, periventricular necrotic brain injury. However, it is associated to high ferritin and low triglycerides at the time of the encephalopathy, other multisystemic injuries, typical neuropathological findings, and recurrence over time, which were not noted in our patient (17). Parvovirus B19 has been described to cause encephalopathy in sickle cell patients. It is associated with aplastic anemia. It caused punctate areas of hemorrhages in the basal ganglia, periventricular white matter, and mainly along the posterior parietal cortex. This was attributed to parvovirus B19-induced vasculitis (18). In our patient, there was no sign of aplasia or any neuroradiological finding of parvovirus B19 infection. Finally, acute encephalitis has been observed in SCD patients in the context of arterial hypoxemia from fat embolism, pulmonary embolism, sudden anemia, or acute chest syndrome due to pneumonia (19). This was ruled out as the patient did not have clinical or radiological signs of acute chest syndrome or embolism and there was no arterial hypoxemia.

Acute hemorrhagic encephalomyelitis has been described in pediatric patients following ADEM or ADEM-like episodes (20, 21). AHEM is the most plausible diagnosis in our patients based on the clinical and radiological presentation, the preceding ADEM-like episode, and the exclusion of other etiologies of acute encephalopathy. Other patients with AHEM have been described in the SCD context (7, 19). Many treatment options have been used to treat AHEM; of these, IV steroids have been associated with survival following aggressive, high-dose corticosteroid therapy (5–9, 22–25).

Autosomal dominant mutations (with incomplete penetrance) in RANBP2 have been associated with susceptibility to infection-induced necrotizing encephalopathy (26, 27). Previously healthy patients with pathogenic mutations in RANBP2 can present acutely with encephalopathy and convulsions in the context of an infection, with brain imaging revealing involvement of the brainstem, thalami, putamina, cerebellum and external capsules, and claustrum (10). Our patient has a similar presentation and imaging features as infection-induced necrotizing encephalopathy, including bilateral thalamic involvement. The rare heterozygous previously unreported variant we identified in RANBP2 affects a very conserved aminoacid and is predicted deleterious using in silico tools (a prediction tool performing a fast bioinformatics

**Figure 2** | Brain magnetic resonance imaging (MRI) (day 30) at the time of the relapse of the neurological manifestations showing left frontoparietal cortical and subcortical areas of isointense T1, high T2 (A), FLAIR (B), and restricted diffusion (C) signals (arrowhead) increasing in size along the MRI examination, due to an active hyperacute bleed [arrow (A) pointing at spot sign indicating active bleed]. Area of high T2 and FLAIR signal changes (arrowheads) in the head of the caudate nucleus (D) and of abnormal diffusion weighed images (DWI) in the subcortical right cerebellar white matter (arrowheads) (E). Previous left midbrain lesion has resolved with only a tiny residual of high FLAIR signal corresponding to minimal residual gliosis (arrowhead) (F). Follow-up brain MRI at D33 showing a necrotico-hemorrhagic lesion in the left hemisphere (G, J), interval evolution of cortical/subcortical lesions, with new lesions in the bilateral thalami (G), cerebellar hemispheres (H), and right cerebral hemisphere (I) (arrowheads indicate abnormal signals).

**Figure 3** | FLAIR sequences of brain magnetic resonance imaging (MRI) at day 39 showing interval evolution and improvement of thalamic (A), cerebellar (B), and right cerebral hemispheric lesions (C) with no additional lesions as compared to the previous MRI (arrowheads indicate hypersignal abnormalities).
Table 1: List of the 45 genes associated with acute hemorrhagic encephalomyelitis/autoimmune inflammatory disorders studied in our patient.

| # | Gene abbreviation | Gene full name | OMIM # | # | Gene abbreviation | Gene full name | OMIM # |
|---|-------------------|----------------|--------|---|-------------------|----------------|--------|
| 1 | AP1S3 | ADAPTOR-RELATED PROTEIN COMPLEX 1, SIGMA-3 SUBUNIT | 615781 | 24 | MYOM2 | MYOMESIN 2 | 603509 |
| 2 | AQP1 | AQUAPORIN 1 | 107776 | 25 | NLRC4 | NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 4 | 606831 |
| 3 | AQP4 | AQUAPORIN 4 | 600308 | 26 | NLRP12 | NLR FAMILY, PYRIN DOMAIN-CONTAINING 12 | 609648 |
| 4 | CARD14 | CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 14 | 607211 | 27 | NLRP3 | NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 | 606416 |
| 5 | CD8A | CD8 ANTIGEN, ALPHA POLYPEPTIDE | 186910 | 28 | NOD2 | NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN PROTEIN 2 | 606956 |
| 6 | CECR1 | CAT EYE SYNDROME CHROMOSOME REGION, CANDIDATE 1 | 607575 | 29 | NLRP12 | NLR FAMILY, PYRIN DOMAIN-CONTAINING 12 | 609648 |
| 7 | ELANE | ELASTASE, NEUTROPHIL-EXPRESSED | 130130 | 30 | NRP1 | NEUROPLIN 1 | 602069 |
| 8 | FASLG | FAS LIGAND | 134638 | 31 | OCLN | OCCLUDIN | 602876 |
| 9 | FLT1 | FMS-RELATED TYROSINE KINASE 1 | 165070 | 32 | PSMB8 | PROTEASOME SUBUNIT, BETATYPE, 8 | 173064 |
| 10 | ITGA4 | INTEGRIN, ALPHA-4 | 165070 | 33 | NLRP3 | NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 | 606416 |
| 11 | IL10 | INTERLEUKIN 10 | 124092 | 34 | NLRP7 | NLR FAMILY, PYRIN DOMAIN-CONTAINING 7 | 609661 |
| 12 | IL1RN | INTERLEUKIN 36 RECEPTOR ANTAGONIST | 605507 | 35 | RANBP2 | RAN BINDING PROTEIN 2 | 601181 |
| 13 | IL2 | INTERLEUKIN 2 | 147679 | 36 | RANBP2 | RAN BINDING PROTEIN 2 | 601181 |
| 14 | IL36RN | INTERLEUKIN 36 RECEPTOR ANTAGONIST | 605507 | 37 | RBCK1 | RANBP-TYPE AND C3HC4-TYPE ZINC FINGER-CONTAINING | 610924 |
| 15 | IFI1 | INTERFERON REGULATORY FACTOR 1 | 147575 | 38 | RPS27A | RIBOSOMAL PROTEIN S27a | 191343 |
| 16 | ITGA4 | INTEGRIN, ALPHA-4 | 192975 | 39 | SH3BP2 | SH3 DOMAIN-BINDING PROTEIN 2 | 602104 |
| 17 | KDR | KINASE INSERT DOMAIN RECEPTOR | 191306 | 40 | SLC29A3 | SOLUTE CARRIER FAMILY 29 (NUCLEOSIDE TRANSPORTER), MEMBER 3 | 612373 |
| 18 | MAP2 | MYELIN BASIC PROTEIN | 151594 | 41 | STAT1 | SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 | 600555 |
| 19 | MAP2 | MYELIN BASIC PROTEIN | 151594 | 42 | TMEM173 | TRANSMEMBRANE PROTEIN 173 | 612374 |
| 20 | MBP | MYELIN BASIC PROTEIN | 151594 | 43 | TNFRSF11A | TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 11A | 603499 |
| 21 | MVK | MEVALONATE KINASE | 251170 | 44 | TNFRSF11A | TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 1A | 191190 |
| 22 | MX1 | MYXOVIRUS RESISTANCE 1 | 251170 | 45 | VEGFA | VASCULAR ENDOTHELIAL GROWTH FACTOR A | 192240 |

Bold characters indicate gene in which potentially pathogenic variant was detected.

Analysis which can predict the pathogenicity of a variant based on the change to an amino acid. It is possible that this variant is pathogenic and responsible for the clinical phenotype. There is an overlap between the diagnostic criteria of AHEM and those of acute hemorrhagic encephalopathy (25, 26) making possible that both entities might be part of the same pathophysiological continuum. RANBP2 is a protein playing an important role in the energy homeostasis of neuronal cells (28). Hence, RANBP2 dysfunction might make neuronal cells much vulnerable to energy failure and necrosis when exposed to inflammatory or other stresses, such as those implicated in AHEM.

**ETHICS STATEMENT**

This study was carried out in accordance with the recommendations of our institutional ethic committee. Written informed consent was obtained from all the participants for the publication.

**AUTHOR CONTRIBUTIONS**

All authors participated in gathering the data, designing the article, and discussing and editing the manuscript.

**ACKNOWLEDGMENTS**

We thank Dr. S. Abish, Dr. N. Ahmed, and Mrs. C. Guiraut for their help. We are grateful to the Hoppenheim Fund from the Montreal Children Hospital Foundation.

**FUNDING**

The first author of this article received a scholarship from the Hoppenheim Fund, Montreal Children Hospital Foundation (2016). This work was supported by grants from Heart and Stroke Foundation of Canada (grant number: G-14-0005756), and Foundation of Stars.
REFERENCES

1. Hurst EW. Acute hemorrhagic leukoencephalitis: a previously undefined entity. Med J Aust (1941) 21:6.
2. Adams RD, Cammermeyer J, Byunyewode D. Acute necrotizing hemorrhagic encephalopathy. J Neuropathol Exp Neurol (1948) 7:111.
3. Martins HM, Teixeira AL, Lana-Peixoto MA; Brazilian Committee for Treatment and Research in Multiple Sclerosis. Acute hemorrhagic leukoencephalitis mimicking herpess simplex encephalitis: case report. Arq Neuropsiquiatr (2004) 62(1):139–43. doi:10.1590/S0004-282X2004000100024
4. Kanter DS, Horensky D, Sperling RA, Kaplan JD, Malachowski ME, Churchill WH. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Neurology (1995) 45(4):824–7. doi:10.1212/WNL.45.4.824
5. Byers RK. Acute hemorrhagic leukoencephalitis: report of three cases and review of the literature. Pediatrics (1975) 56(5):727–35.
6. Stone MJ, Hawkins CP. A medical overview of encephalitis. Neuropsychol Rehabil (2007) 17(4–5):429–49. doi:10.1080/09602010601069430
7. Jagen J, Bolt C, Melbourne-Chambers R, MooSang M. Acute hemorrhagic leukoencephalitis in a patient with sickle cell disease: a case report. Internet J Pathol (2008) 8(2). Available from: http://ispub.com/JIPA/8/2/5726
8. Leake JAD, Billman GF, Nespeca MP, Duthie SE, Dory CE, Meltzer HS, et al. Pediatric acute hemorrhagic leukoencephalitis: report of a surviving patient and review. Clin Infect Dis (2002) 34(5):699–703. doi:10.1086/338718
9. Payne ET, Rutka JT, Ho TK, Halliday WC, Banwell BL. Treatment leading to dramatic recovery in acute hemorrhagic leukoencephalitis. J Child Neurol (2007) 22(1):109–13. doi:10.1177/0883073707299971
10. Lönnqvist T, Iohannii P, Valanne L, Olli-Lähesmäki T, Suomalainen A, Pikho H. Dominant encephalopathy mimicking mitochondrial disease. Neurology (2011) 76(1):101–3. doi:10.1212/WNL.0b013e318203e908
11. Martin A, Reade EP. Acute necrotizing encephalopathy progressing to brain death in a pediatric patient with novel influenza A (H1N1) infection. Clin Infect Dis (2010) 50(8):e50–2. doi:10.1086/651501
12. DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood (2016) 127(7):829–38. doi:10.1182/blood-2015-09-618579
13. Strouse JJ, Hulbert ML, DeBaun MR, Jordan LC, Casella JF. Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics (2006) 118(5):1916–24. doi:10.1542/peds.2006-1241
14. Kolovou V, Vampakis P, Ginopoulou A, Varvarigou A, Kalyevas J. Reversible posterior leukoencephalopathy syndrome after blood transfusion in a pediatric patient with sickle cell disease. Pediatr Neurol (2013) 49(3):213–7. doi:10.1016/j.pediatrneurol.2013.04.024
15. Soli Z, Taccone MS, Marin S, Athale U, Breakey VR. Neurological presentations in sickle cell patients are not always stroke: a review of posterior reversible encephalopathy syndrome in sickle cell disease. Pediatr Blood Cancer (2016) 63(6):983–9. doi:10.1002/pbc.25932
16. Khademian Z, Speller-Brown B, Nourae S-M, Minniti CP. Reversible posterior leukoencephalopathy in children with sickle cell disease. Pediatr Blood Cancer (2009) 52(3):373–5. doi:10.1002/pbc.21812
17. Hashim HZ, Ibrahim NM, Wanyahya N, Tan HJ, Zainun KA, Mohd Ali SA, et al. A case of biopsy proven acute demyelinating encephalomyelitis (ADEM) with haemorrhagic leukoencephalitis. Ann Acad Med Singapore (2011) 40(4):197–200.
18. Bakshi S, Sarnaik SA, Becker C, Shurney WW, Nigro M, Savaşan S. Acute encephalopathy with parvovirus B19 infection in sickle cell disease. Arch Dis Child (2002) 87(6):541–2. doi:10.1136/adc.87.6.541
19. Lee KH, McKie VC, Sekul EA, Adams RJ, Nichols FT. Unusual encephalopathy after acute chest syndrome in sickle cell disease: acute necrotizing encephalitis. J Pediatr Hematol Oncol (2002) 24(7):585–8. doi:10.1097/0158200200000000021
20. Borlot F, da Paz JA, Casella EB, Marques-Dias MJ. Acute hemorrhagic encephalomyelitis in childhood: case report and literature review. J Pediatr Neurosci (2011) 6(1):48–51. doi:10.14103/1817-1745.84408
21. Dangond F, Lacomis D, Schwartz RB, Wen PY, Samuels MA. Acute disseminated encephalomyelitis progressing to hemorrhagic encephalitis. Neurology (1991) 41(10):1697–8. doi:10.1212/WNL.41.10.1697
22. Okumura A, Mizuguchi M, Kidokoro H, Tanaka M, Abe S, Hosoya M, et al. Outcome of acute necrotizing encephalopathy in relation to treatment with corticosteroids and gammaglobulin. Brain Dev (2009) 31S:221–7. doi:10.1016/j.braindev.2008.03.005
23. Yamamoto K, Chiba HO, Ishitobi M, Nakagawa H, Ogawa T, Ishii K. Acute encephalopathy with bilateral striatal necrosis: favourable response to corticosteroid therapy. Eur J Paediatr Neurol (2011) 17(1):41–5. doi:10.1016/ S1090-3798(10)80010-4
24. Rosman NP, Gottlieb SM, Bernstein CA. Acute hemorrhagic leukoencephalitis: recovery and reversal of magnetic resonance imaging findings in a child. J Child Neurol (1997) 12(7):448–54. doi:10.1177/088307370701200707
25. Iyer A, Elson E, Appleton R, Jacob A. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity (2014) 47(3):154–61. doi:10.3109/0891934.2014.883501
26. Neilson DE, Adams MD, Orr CMD, Schelling DK, Eiben RM, Kerr DS, et al. Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RanBP2. Am J Hum Genet (2009) 84(1):44–51. doi:10.1016/j.ajhg.2008.12.009
27. Singh RR, Sedani S, Lim M, Wassmer E, Absoud M. RanBP2 mutation and acute necrotizing encephalopathy: 2 cases and a literature review of the expanding clinico-radiological phenotype. Eur J Paediatr Neurol (2015) 19(2):106–13. doi:10.1016/j.ejpn.2014.11.010
28. Aslanukov A, Bhowmick R, Guruju M, Oswald J, Raz D, Bush RA, et al. RanBP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of RanBP2 causes deficits in glucose metabolism. PLoS Genet (2006) 2(10):e177. doi:10.1371/journal.pgen.0020177

Conflict of Interest Statement: There is no conflict of interest. This manuscript has been seen and approved by all co-authors. All the authors fulfill the authorship credit requirements. AA wrote the first draft of this manuscript. No honorarium grant or other form of payment was received for the preparation of this manuscript.

Copyright © 2018 Alawadhi, Saint-Martins, Bhanji, Srour, Atkinson and Sébire. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.